Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis

@article{Kim2015AnticancerAO,
  title={Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis},
  author={Dong Geon Kim and Younggeon Jin and Juyoun Jin and Heekyoung Yang and K. Joo and W. Lee and S. R. Shim and Sung-Woo Kim and J. Yoo and S. Lee and Jin-San Yoo and D. Nam},
  journal={mAbs},
  year={2015},
  volume={7},
  pages={1195 - 1204}
}
Vascular endothelial growth factor (VEGF) and its receptors are considered the primary cause of tumor-induced angiogenesis. [...] Key Method To assess the efficacy of the antibody and pharmacokinetic (PK) relationship in vivo, we tested the potency of TTAC-0001 in glioblastoma and colorectal cancer xenograft models. Antitumor activity of TTAC-0001 in preclinical models correlated with tumor growth arrest, induction of tumor cell apoptosis, and inhibition of angiogenesis. We also evaluated the combination effect…Expand
TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
Angelicin inhibits liver cancer growth in vitro and in vivo
A fully human anti-CD47 blocking antibody with therapeutic potential for cancer
MicroRNA-370 suppresses the retinal capillary endothelial cell growth by targeting KDR gene.
Targeting Malignant Brain Tumors with Antibodies
The Effects of Taoren-Honghua Herb Pair on Pathological Microvessel and Angiogenesis-Associated Signaling Pathway in Mice Model of CCl4-Induced Chronic Liver Disease
NMR mapping of the highly flexible regions of 13C/15N-labeled antibody TTAC-0001-Fab.
...
1
2
...

References

SHOWING 1-10 OF 54 REFERENCES
TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
...
1
2
3
4
5
...